CPS
  • Home

Sign in or register to track your progress, save, and view your completed history.

Breast Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head & Neck Cancer, Urothelial Carcinoma

A Systematic Approach to Scoring Combined Positive Score (CPS) Using Agilent’s PD-L1 IHC 22C3 pharmDx Assay

    clockimg 62m
  • Webinar
  • Foundational
 saveimgSave unsaveimgUnsave

The Precision Pathology Insights webinar series provides expert guidance and essential approaches to help enhance your confidence in Combined Positive Score (CPS) evaluation and strengthen your PD-L1 proficiency. In this webinar, Dr. Alexandros Polydorides reviews various cases that examine the components determining PD-L1 expression levels of various specimens. The webinar is moderated by Douglas P. Clark, MD, Chief Pathologist of Agilent Technologies CDx Division. Recorded on 13 May 2025.​

Join us for expert insights into CPS from the Vice Chair for Clinical Research in the Department of Pathology at Mount Sinai, Dr. Alexandros Polydorides:

  • Indication-specific staining characteristics and morphologies that may impact CPS evaluation
  • Scoring demonstrations
  • Tips to ensure accurate and efficient evaluation
  • Interactive Q&A session for discussion and questions

Dr. Alexandros Polydorides

Vice Chair for Clinical Research and Trial Design, Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York

Douglas P. Clark, M.D.

Chief Pathologist, CDx Division, Agilent Technologies

Related Training

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.D0128830_1.00